A Structural Analysis of the FDA Green Book-Approved Veterinary Drugs and Roles in Human Medicine
A Structural Analysis of the FDA Green Book-Approved Veterinary Drugs and Roles in Human Medicine
复制标题
DOI：
10.1021/acs.jmedchem.0c01502
复制
发表时间：
2020-12-24
影响因子：
7.3
通讯作者：
Njardarson, Jon T.
中科院分区：
文献类型：
--
作者：
Scott, Kevin A.;Qureshi, M. Haziq;Njardarson, Jon T.
FDA绿色手册是FDA批准用于兽药的所有药品的列表。出版的这本绿色书缺乏与已批准药物相对应的结构信息。为了解决这一差距，我们编制了截至2019年底批准的所有FDA绿色书药物的结构数据。在这里，我们讨论了这一数据集的结构类别和理化性质的背景下，人类药物的相关性。分析表明，理化性质是高度优化的，并且与有利的药物代谢和药代动力学性质的高概率一致，包括大多数化合物的良好口服生物利用度。我们提供了一个详细的分析，这个数据集的结构和功能的基础上组织。略超过一半（51%）的兽医药物也被批准用于人类药物。还讨论了组合药物是生物制剂。
The FDA Green Book is a list of all drug products that have been approved by the FDA for use in veterinary medicine. The Green Book, as published, lacks structural information corresponding to approved drugs. To address this gap, we have compiled the structural data for all FDA Green Book drugs approved through the end of 2019. Herein we discuss the relevance of this data set to human drugs in the context of structural classes and physicochemical properties. Analysis reveals that physicochemical properties are highly optimized and consistent with a high probability of favorable drug metabolism and pharmacokinetic properties, including good oral bioavailability for most compounds. We provide a detailed analysis of this data set organized on the basis of structure and function. Slightly over half (51%) of vet drugs are also approved in human medicine. Combination drugs are biologics are also discussed.